论文部分内容阅读
目的观察益肾康颗粒联合厄贝沙坦治疗糖尿病肾病的临床疗效,为益肾康颗粒的临床应用提供依据。方法选取2013年6月—2015年12月于本院就诊的糖尿病肾病患者共140例,随机分为对照组和观察组各70例,两组除给予降血糖、调血脂等基础治疗外,均口服厄贝沙坦;观察组组在对照组的基础上采用口服益肾康颗粒。观察两组患者治疗前后临床症状、血糖、24 h尿蛋白排泄率(24 hours urinary albumin excretion rate,24 h UAER)、内生肌酐清除率(creatinine clearance rate,Ccr)及临床疗效。计量资料比较采用t检验,计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果治疗后两组患者腰痛腰酸、肢体浮肿、口干咽燥、神疲乏力评分比较[(1.54±0.67)、(1.51±0.78)、(0.78±0.45)、(1.48±0.72)分,(1.14±0.69)、(1.07±0.53)、(0.53±0.39)、(1.05±0.76)分],差异均有统计学意义(均P<0.05)。观察组患者治疗前后各症状评分比较,差异均有统计学意义(均P<0.05)。治疗后两组患者24 h UAER、Ccr比较[(175.72±23.45)μg/min、(89.43±8.62)ml/min,(138.83±26.85)μg/min、(93.37±7.56)ml/min],差异均有统计学意义(均P<0.05)。治疗前后两组患者实验室各指标分别比较,差异均有统计学意义(均P<0.05)。对照组总有效率为68.57%(48/70),观察组为88.57%(62/70),两组对比差异有统计学意义(P<0.05)。结论益肾康颗粒联合厄贝沙坦治疗糖尿病肾病能够改善患者的生存质量,提高临床疗效和患者的满意度,且中西医结合治疗方法具有降糖作用平稳,不良反应等优点,值得临床推广使用。
Objective To observe the clinical efficacy of YISHIZANG granules combined with irbesartan in the treatment of diabetic nephropathy and provide the basis for the clinical application of YISHENKANG granules. Methods A total of 140 diabetic nephropathy patients treated in our hospital from June 2013 to December 2015 were randomly divided into control group and observation group of 70 cases. Except for the basic therapy of lowering blood glucose and blood lipid, Oral administration of irbesartan; observation group in the control group based on oral Yishenkang granules. The clinical symptoms, blood glucose, 24h urinary albumin excretion rate (24 h UAER), creatinine clearance rate (Ccr) and clinical efficacy were observed before and after treatment. Measurement data were compared using t test, count data were compared using χ2 test, P <0.05 for the difference was statistically significant. Results After treatment, the scores of lumbago, backache and throat were lower in the two groups ([1.54 ± 0.67], (1.51 ± 0.78), (0.78 ± 0.45), (1.48 ± 0.72), ± 0.69), (1.07 ± 0.53), (0.53 ± 0.39) and (1.05 ± 0.76) points respectively. The difference was statistically significant (all P <0.05). Before and after treatment, the score of each symptom in the observation group was significantly different (all P <0.05). The difference of UAER and Ccr between the two groups after 24 h of treatment was (175.72 ± 23.45) μg / min, (89.43 ± 8.62) ml / min, (138.83 ± 26.85) μg / min and (93.37 ± 7.56) ml / min] All were statistically significant (P <0.05). Before and after treatment in the two groups of laboratory indicators were compared, the differences were statistically significant (P <0.05). The total effective rate was 68.57% (48/70) in the control group and 88.57% (62/70) in the observation group. The difference between the two groups was statistically significant (P <0.05). Conclusion Yishenkang granule combined with irbesartan in the treatment of diabetic nephropathy can improve the quality of life of patients and improve the clinical efficacy and patient satisfaction, and the combination of traditional Chinese and Western medicine has the advantages of stable hypoglycemic effect, adverse reactions, etc., worthy of clinical promotion .